Developer docs
API playgroundTry for free, no card

Search company profiles

Casma Therapeutics

Full company profile

uuid0000fon

Namestring
Casma Therapeutics
Legal namestring
Casma Therapeutics, Inc.
Websiteurl
casmatx.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Casma Therapeutics is a privately held, preclinical-stage biotechnology company founded in 2018 and headquartered in Cambridge, Massachusetts, that develops novel therapeutics by harnessing autophagy — the cell's natural lysosomal degradation pathway. The company's proprietary PHLYT™ (Phagosome-Lysosome Targeting) platform uses heterobifunctional small-molecule chemistry to initiate target-specific autophagic degradation of disease-related cellular components, including organelles, protein aggregates, and large signaling complexes that are beyond the capacity of conventional ubiquitin-proteasome or E3 ligase-based degraders. Casma's pipeline is anchored by CSM-101, a first-in-class orally bioavailable, CNS-penetrant small-molecule agonist of TRPML1 (a critical lysosomal ion channel) nominated in June 2025 as its first development candidate for Gaucher's disease patients with Parkinson's disease, with expansion potential into GBA-associated and broader Parkinson's populations. Additional discovery-stage programs target MYD88 mutant lymphoma via the PHLYT™ degrader platform, muscular dystrophy through TRPML1-mediated plasma membrane repair, and lysosomal storage disorders.

The company has raised approximately $154.5 million in cumulative equity financing across a $58.5M Series A (2018, Third Rock Ventures), $50M Series B (2020, led by The Column Group), and $46M Series C (2022, with Amgen Ventures, Astellas, Eisai, and others), plus $7.6M in non-dilutive grant funding from The Michael J. Fox Foundation awarded in March 2026. Casma has no approved products and generates no commercial revenue; its primary customers in the future will be patients with neurodegenerative diseases, oncology indications, and lysosomal storage disorders, with go-to-market likely via partnership with large pharmaceutical companies or independent commercialization following clinical development. The scientific founding team comprises globally recognized autophagy researchers (Andrea Ballabio, Beth Levine, James Hurley, Herbert 'Skip' Virgin), and an IND filing for CSM-101 is planned for the first half of 2026.

Short descriptiontext

Casma Therapeutics is a preclinical-stage biotechnology company developing autophagy-based therapeutics via its proprietary PHLYT™ platform, with lead asset CSM-101 — a first-in-class TRPML1 agonist for Parkinson's and Gaucher's disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
autophagy drug discovery, targeted protein degradation, lysosomal therapeutics, small molecule pharmaceuticals, neurodegeneration therapeutics
Industry3 codes
PRIMARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Autophagy-based Therapeutics / Targeted Protein Degradation
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical Development
TypeOne Time License
Description

Pre-revenue biotechnology company developing novel therapeutics based on autophagy pathway. No approved products or commercial revenue yet. Revenue generation expected upon successful clinical development and regulatory approval of drug candidates.

casmatx.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Casma Therapeutics is a preclinical-stage biotechnology company developing novel therapeutics that harness the autophagy pathway to selectively degrade disease-causing cellular components beyond the capacity of the ubiquitin-proteasome system. Its proprietary PHLYT™ (Phagosome-Lysosome Targeting) platform uses heterobifunctional chemistry to recruit autophagy regulators to disease targets, enabling degradation of large and complex substrates such as organelles, protein aggregates, and signaling complexes. The lead clinical-stage asset is CSM-101, a first-in-class, orally bioavailable, CNS-penetrant small-molecule TRPML1 agonist for Gaucher's disease patients with Parkinson's disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • CSM-101 demonstrated high CNS exposure, potent activity across clinically relevant models, significant reductions in toxic lipid levels, decreased neuroinflammation, and improved survival in multiple Gaucher's disease models
+2 more records
Product overview1 text field

Casma Therapeutics is a biotechnology company developing novel cellular degradation approaches based on the autophagy pathway. The company's core offering is the PHLYT™ (Phagosome-Lysosome Targeting) platform, which enables selective autophagic degradation of disease targets beyond the capacity of traditional ubiquitin-proteasome approaches. The company's lead product is CSM-101, a first-in-class TRPML1 agonist for Parkinson's disease and Gaucher's disease. The pipeline includes multiple PHLYT™ programs in oncology and Parkinson's disease, as well as an mTOR-independent autophagy agonist program, all at discovery or preclinical stages.

Product and service4 records
1PHLYT™ (Phagosome-Lysosome Targeting) Platform
CategoryTherapeutic Platform / Drug Discovery Engine
Description

Proprietary heterobifunctional chemistry platform that recruits autophagy regulators to disease targets to drive autophagosome biogenesis around the substrate, enabling selective degradation of organelles, protein aggregates, and large signaling complexes beyond the capacity of E3 ligase or proteasomal degraders. Applied across oncology, inflammation, neurodegeneration, and metabolic disorders.

2CSM-101 (TRPML1 Agonist)
CategoryDrug Candidate — Neurodegeneration
Description

Lead clinical-stage asset: a first-in-class, orally bioavailable, CNS-penetrant small molecule agonist of TRPML1, a critical lysosomal ion channel. Designed to restore lysosomal function in patients with Gaucher's disease with Parkinson's disease (GD-PD), with potential expansion to GBA-PD and idiopathic Parkinson's disease.

3TRPML1 Agonist CNS Program
CategoryDrug Candidate — Neurodegeneration
Description

Pipeline program targeting the TRPML1 lysosomal ion channel to enhance lysosomal efficiency and modulate dynamics in CNS diseases where lysosomal function is compromised, including neurodegeneration.

4MYD88 Mutant Lymphoma Program (Autophagy Degrader)
CategoryDrug Candidate — Oncology
Description

Autophagy degrader program using the PHLYT™ platform to develop degraders targeting disease drivers in MYD88 mutant lymphoma.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2020-12-01
Description

Drug discovery agreement where Vipergen applies its proprietary high-fidelity DNA-encoded library (DEL) technology platform to discover novel small-molecule drug leads against undisclosed Casma discovery targets. Casma retains exclusive rights to globally commercialize any products resulting from the collaboration.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-09-11
Description

Research collaboration to develop new therapies for lysosomal storage disorders and common disorders such as neurodegeneration. The partnership combines Casma's autophagy biology and drug discovery expertise with TIGEM's clinical experience and insights into rare genetic diseases. TIGEM is led by Casma founder Andrea Ballabio, M.D., director of TIGEM.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Arvinas is a clinical-stage targeted protein degradation company pioneering PROTAC-based bifunctional degraders. It is the closest functional peer to Casma, sharing a heterobifunctional degrader chemistry paradigm and a goal of eliminating disease-driving proteins, although Casma routes degradation through the lysosome via autophagy rather than the proteasome via E3 ligases.

TypeDirect peer
Description

Kymera is a clinical-stage biotech developing heterobifunctional small-molecule degraders leveraging E3 ligase chemistry. It competes with Casma in the broader targeted-degradation space and shares a similar platform-plus-pipeline business model aimed at oncology and immunology indications.

TypeDirect peer
Description

C4 Therapeutics develops targeted protein degraders using its TORPEDO platform, a heterobifunctional small-molecule approach conceptually adjacent to Casma's PHLYT™. Both companies pursue degrader-based therapies across oncology indications.

TypeDirect peer
Description

Lycia is pioneering LYTAC (lysosome-targeting chimera) degraders that route disease targets to the lysosome for degradation. Casma's autophagy-based PHLYT™ platform shares the lysosomal-degradation mechanism, making Lycia a close mechanistic peer in the emerging 'extracellular and organelle-targeted degradation' category.

TypeDirect peer
Description

Monte Rosa develops molecular glue degraders (MGDs) to selectively degrade disease-driving proteins via the ubiquitin-proteasome system. It is a relevant peer in the broader targeted-degradation field with a comparable platform-company business model, though differentiated from Casma's autophagy/lysosomal mechanism.

TypeEmerging player
Description

Denali is a clinical-stage biotech developing therapeutics for neurodegenerative diseases, with active programs in Parkinson's and lysosomal storage disorders. It overlaps with Casma's CNS-penetrant TRPML1 agonist approach (CSM-101) for GBA-PD and broader PD, though Denali uses enzyme replacement and antibody-based modalities rather than autophagy induction.

TypeEmerging player
Description

Prothena is a clinical-stage biotech developing protein-immunotherapy approaches for neurodegenerative diseases, including alpha-synuclein-targeted therapies for Parkinson's. It addresses the same GBA-PD and idiopathic PD populations targeted by CSM-101, representing a competing disease-modifying approach.

TypeBroad incumbent
Description

BioMarin is an established global biopharmaceutical company with multiple approved enzyme-replacement therapies for lysosomal storage disorders. Casma's autophagy-enhancer approach to LSDs (clearance of accumulated substrates) represents an alternative modality to BioMarin's enzyme replacement, and BioMarin is the dominant incumbent partner/buyer in this therapeutic space.

TypeEmerging player
Description

Foghorn is a clinical-stage biotech using a chromatin biology platform to develop small-molecule therapies in oncology. Like Casma, Foghorn is a platform-driven biotech leveraging proprietary biology (chromatin regulatory complexes vs. autophagy machinery) to address previously undruggable disease targets.

10Navitor Pharmaceuticals
TypeEmerging player
Description

Navitor developed small molecules targeting the mTOR pathway, which is mechanistically upstream of autophagy regulation. While its chemistry is different, Navitor's focus on mTOR/autophagy signaling overlap with Casma's mTOR-independent autophagy agonist program and broader autophagy-biology thesis.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Casma Therapeutics

Autophagy-based Therapeutics / Targeted Protein Degradationcasmatx.com

Casma Therapeutics is a preclinical-stage biotechnology company developing autophagy-based therapeutics via its proprietary PHLYT™ platform, with lead asset CSM-101 — a first-in-class TRPML1 agonist for Parkinson's and Gaucher's disease.

What Casma Therapeutics does

Casma Therapeutics is a privately held, preclinical-stage biotechnology company founded in 2018 and headquartered in Cambridge, Massachusetts, that develops novel therapeutics by harnessing autophagy — the cell's natural lysosomal degradation pathway. The company's proprietary PHLYT™ (Phagosome-Lysosome Targeting) platform uses heterobifunctional small-molecule chemistry to initiate target-specific autophagic degradation of disease-related cellular components, including organelles, protein aggregates, and large signaling complexes that are beyond the capacity of conventional ubiquitin-proteasome or E3 ligase-based degraders. Casma's pipeline is anchored by CSM-101, a first-in-class orally bioavailable, CNS-penetrant small-molecule agonist of TRPML1 (a critical lysosomal ion channel) nominated in June 2025 as its first development candidate for Gaucher's disease patients with Parkinson's disease, with expansion potential into GBA-associated and broader Parkinson's populations. Additional discovery-stage programs target MYD88 mutant lymphoma via the PHLYT™ degrader platform, muscular dystrophy through TRPML1-mediated plasma membrane repair, and lysosomal storage disorders.

The company has raised approximately $154.5 million in cumulative equity financing across a $58.5M Series A (2018, Third Rock Ventures), $50M Series B (2020, led by The Column Group), and $46M Series C (2022, with Amgen Ventures, Astellas, Eisai, and others), plus $7.6M in non-dilutive grant funding from The Michael J. Fox Foundation awarded in March 2026. Casma has no approved products and generates no commercial revenue; its primary customers in the future will be patients with neurodegenerative diseases, oncology indications, and lysosomal storage disorders, with go-to-market likely via partnership with large pharmaceutical companies or independent commercialization following clinical development. The scientific founding team comprises globally recognized autophagy researchers (Andrea Ballabio, Beth Levine, James Hurley, Herbert 'Skip' Virgin), and an IND filing for CSM-101 is planned for the first half of 2026.

Casma Therapeutics firmographics

Firmographics
Name
Casma Therapeutics
Legal name
Casma Therapeutics, Inc.
Website
https://casmatx.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Casma Therapeutics is a preclinical-stage biotechnology company developing autophagy-based therapeutics via its proprietary PHLYT™ platform, with lead asset CSM-101 — a first-in-class TRPML1 agonist for Parkinson's and Gaucher's disease.
Ownership category
akta.pro rank

Casma Therapeutics industry classification

Industry
Product category
Autophagy-based Therapeutics / Targeted Protein Degradation
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Autophagy drug discovery
  • Targeted protein degradation
  • Lysosomal therapeutics
  • Small molecule pharmaceuticals
  • Neurodegeneration therapeutics

Where Casma Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Casma Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Biopharmaceutical Development: Pre-revenue biotechnology company developing novel therapeutics based on autophagy pathway. No approved products or commercial revenue yet. Revenue generation expected upon successful clinical development and regulatory approval of drug candidates.

Go-to-market motion2 records

Marketing channels6 records

Casma Therapeutics product offering

Product offering

Core offering

Casma Therapeutics is a preclinical-stage biotechnology company developing novel therapeutics that harness the autophagy pathway to selectively degrade disease-causing cellular components beyond the capacity of the ubiquitin-proteasome system. Its proprietary PHLYT™ (Phagosome-Lysosome Targeting) platform uses heterobifunctional chemistry to recruit autophagy regulators to disease targets, enabling degradation of large and complex substrates such as organelles, protein aggregates, and signaling complexes. The lead clinical-stage asset is CSM-101, a first-in-class, orally bioavailable, CNS-penetrant small-molecule TRPML1 agonist for Gaucher's disease patients with Parkinson's disease.

Product overview

Casma Therapeutics is a biotechnology company developing novel cellular degradation approaches based on the autophagy pathway. The company's core offering is the PHLYT™ (Phagosome-Lysosome Targeting) platform, which enables selective autophagic degradation of disease targets beyond the capacity of traditional ubiquitin-proteasome approaches. The company's lead product is CSM-101, a first-in-class TRPML1 agonist for Parkinson's disease and Gaucher's disease. The pipeline includes multiple PHLYT™ programs in oncology and Parkinson's disease, as well as an mTOR-independent autophagy agonist program, all at discovery or preclinical stages.

Differentiator

Problem solved

Functional benefit

Products and services

  • PHLYT™ (Phagosome-Lysosome Targeting) Platform Proprietary heterobifunctional chemistry platform that recruits autophagy regulators to disease targets to drive autophagosome biogenesis around the substrate, enabling selective degradation of organelles, protein aggregates, and large signaling complexes beyond the capacity of E3 ligase or proteasomal degraders. Applied across oncology, inflammation, neurodegeneration, and metabolic disorders.
  • CSM-101 (TRPML1 Agonist) Lead clinical-stage asset: a first-in-class, orally bioavailable, CNS-penetrant small molecule agonist of TRPML1, a critical lysosomal ion channel. Designed to restore lysosomal function in patients with Gaucher's disease with Parkinson's disease (GD-PD), with potential expansion to GBA-PD and idiopathic Parkinson's disease.
  • TRPML1 Agonist CNS Program Pipeline program targeting the TRPML1 lysosomal ion channel to enhance lysosomal efficiency and modulate dynamics in CNS diseases where lysosomal function is compromised, including neurodegeneration.
  • MYD88 Mutant Lymphoma Program (Autophagy Degrader) Autophagy degrader program using the PHLYT™ platform to develop degraders targeting disease drivers in MYD88 mutant lymphoma.

Quantifiable outcome

  • CSM-101 demonstrated high CNS exposure, potent activity across clinically relevant models, significant reductions in toxic lipid levels, decreased neuroinflammation, and improved survival in multiple Gaucher's disease models
  • +2 more outcomes

Companies that use Casma Therapeutics

Customer profile

Segments4 records

Ideal customer profiles3 records

Casma Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Casma Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered supporting and core.

  • Vipergen ApSsupportingTechnology or Integration · 1 December 2020Drug discovery agreement where Vipergen applies its proprietary high-fidelity DNA-encoded library (DEL) technology platform to discover novel small-molecule drug leads against undisclosed Casma discovery targets. Casma retains exclusive rights to globally commercialize any products resulting from the collaboration.
  • Fondazione Telethon / TIGEM (Telethon Institute of Genetics and Medicine)coreStrategic or Co-development Partner · 11 September 2018Research collaboration to develop new therapies for lysosomal storage disorders and common disorders such as neurodegeneration. The partnership combines Casma's autophagy biology and drug discovery expertise with TIGEM's clinical experience and insights into rare genetic diseases. TIGEM is led by Casma founder Andrea Ballabio, M.D., director of TIGEM.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Casma Therapeutics competitors and assessment

Company assessment

Direct peers

  • Arvinas: Arvinas is a clinical-stage targeted protein degradation company pioneering PROTAC-based bifunctional degraders. It is the closest functional peer to Casma, sharing a heterobifunctional degrader chemistry paradigm and a goal of eliminating disease-driving proteins, although Casma routes degradation through the lysosome via autophagy rather than the proteasome via E3 ligases.
  • Kymera Therapeutics: Kymera is a clinical-stage biotech developing heterobifunctional small-molecule degraders leveraging E3 ligase chemistry. It competes with Casma in the broader targeted-degradation space and shares a similar platform-plus-pipeline business model aimed at oncology and immunology indications.
  • C4 Therapeutics: C4 Therapeutics develops targeted protein degraders using its TORPEDO platform, a heterobifunctional small-molecule approach conceptually adjacent to Casma's PHLYT™. Both companies pursue degrader-based therapies across oncology indications.
  • Lycia Therapeutics: Lycia is pioneering LYTAC (lysosome-targeting chimera) degraders that route disease targets to the lysosome for degradation. Casma's autophagy-based PHLYT™ platform shares the lysosomal-degradation mechanism, making Lycia a close mechanistic peer in the emerging 'extracellular and organelle-targeted degradation' category.
  • Monte Rosa Therapeutics: Monte Rosa develops molecular glue degraders (MGDs) to selectively degrade disease-driving proteins via the ubiquitin-proteasome system. It is a relevant peer in the broader targeted-degradation field with a comparable platform-company business model, though differentiated from Casma's autophagy/lysosomal mechanism.

Emerging players

  • Denali Therapeutics: Denali is a clinical-stage biotech developing therapeutics for neurodegenerative diseases, with active programs in Parkinson's and lysosomal storage disorders. It overlaps with Casma's CNS-penetrant TRPML1 agonist approach (CSM-101) for GBA-PD and broader PD, though Denali uses enzyme replacement and antibody-based modalities rather than autophagy induction.
  • Prothena Corporation: Prothena is a clinical-stage biotech developing protein-immunotherapy approaches for neurodegenerative diseases, including alpha-synuclein-targeted therapies for Parkinson's. It addresses the same GBA-PD and idiopathic PD populations targeted by CSM-101, representing a competing disease-modifying approach.
  • Foghorn Therapeutics: Foghorn is a clinical-stage biotech using a chromatin biology platform to develop small-molecule therapies in oncology. Like Casma, Foghorn is a platform-driven biotech leveraging proprietary biology (chromatin regulatory complexes vs. autophagy machinery) to address previously undruggable disease targets.
  • Navitor Pharmaceuticals: Navitor developed small molecules targeting the mTOR pathway, which is mechanistically upstream of autophagy regulation. While its chemistry is different, Navitor's focus on mTOR/autophagy signaling overlap with Casma's mTOR-independent autophagy agonist program and broader autophagy-biology thesis.

Broad incumbents

  • BioMarin Pharmaceutical: BioMarin is an established global biopharmaceutical company with multiple approved enzyme-replacement therapies for lysosomal storage disorders. Casma's autophagy-enhancer approach to LSDs (clearance of accumulated substrates) represents an alternative modality to BioMarin's enzyme replacement, and BioMarin is the dominant incumbent partner/buyer in this therapeutic space.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Casma Therapeutics social profiles

Digital presence

Casma Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Casma Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Casma Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Casma Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Casma Therapeutics

What does Casma Therapeutics do?

Casma Therapeutics is a preclinical-stage biotechnology company developing novel therapeutics that harness the autophagy pathway to selectively degrade disease-causing cellular components beyond the capacity of the ubiquitin-proteasome system. Its proprietary PHLYT™ (Phagosome-Lysosome Targeting) platform uses heterobifunctional chemistry to recruit autophagy regulators to disease targets, enabling degradation of large and complex substrates such as organelles, protein aggregates, and signaling complexes. The lead clinical-stage asset is CSM-101, a first-in-class, orally bioavailable, CNS-penetrant small-molecule TRPML1 agonist for Gaucher's disease patients with Parkinson's disease.

Is Casma Therapeutics a public or private company?

Casma Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Casma Therapeutics founded?

Casma Therapeutics was founded in 2018. It employs 11 to 50 people.

Where is Casma Therapeutics based?

Casma Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Casma Therapeutics make money?

One revenue line is on record: biopharmaceutical Development.

Who are Casma Therapeutics's main competitors?

Direct peers on record are Arvinas, Kymera Therapeutics, C4 Therapeutics, Lycia Therapeutics and Monte Rosa Therapeutics. Emerging players are Denali Therapeutics, Prothena Corporation, Foghorn Therapeutics and Navitor Pharmaceuticals. BioMarin Pharmaceutical is listed as a broad incumbent.

Does Casma Therapeutics have an API?

No public API is recorded for Casma Therapeutics.

What industry is Casma Therapeutics in?

Casma Therapeutics's product category is Autophagy-based Therapeutics / Targeted Protein Degradation. Its primary akta.pro industry code is HLAGAJAE, Cheminformatics & Molecular Modeling / CADD, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Parkinsonsnewstoday$7.6M in MJFF grants will help Casma develop Parkinson’s therapyCasma Therapeutics has received $7.6 million from The Michael J. Fox Foundation to support the preclinical development of its CSM-101 therapy for Parkinson's disease. The funding will assist in validating TRPML1 as a therapeutic target and advancing CSM-101 into first-in-human clinical trials. The initiative represents a significant step toward addressing gaps in treatment strategies for Parkinson's disease.Pulse 2.0Casma Therapeutics: $7.6 Million MJFF Funding To Advance TRPML1 Agonist CSM-101 For Parkinson’s DiseaseCasma Therapeutics received $7.6 million from the Michael J. Fox Foundation to advance its TRPML1 agonist CSM-101 for Parkinson's disease. The funding covers $2.1 million for biomarker development and $5.5 million for IND-enabling studies, with preclinical data showing reduced toxic alpha-synuclein and preserved dopaminergic neurons.CasmatxCasma Therapeutics Receives MJFF Support to Advance Research on TRPML1 in Parkinson’s DiseaseCasma Therapeutics has been awarded approximately $7.6 million in non-dilutive funding from The Michael J. Fox Foundation for Parkinson's Research to support IND-enabling activities for its lead program CSM-101, a first-in-class TRPML1 agonist targeting lysosomal dysfunction in Parkinson's disease. The funding comprises a $2.1 million Targets to Therapies grant for biomarker development and a $2.1 million complementary grant, enabling the company to advance toward first-in-human clinical studies.BioSpaceCasma Therapeutics Receives MJFF Support to Advance Research on TRPML1 in Parkinson’s DiseaseCasma Therapeutics received approximately $7.6 million in funding from The Michael J. Fox Foundation for Parkinson’s Research to support preclinical development of its drug CSM-101, a TRPML1 agonist, aimed at treating neurodegenerative diseases related to lysosomal dysfunction. The funding includes two grants to support biomarker development and IND-enabling studies, advancing CSM-101 toward clinical trials.MorningstarCasma Therapeutics Receives MJFF Support to Advance Research on TRPML1 in Parkinson’s DiseaseCasma Therapeutics has been awarded approximately $7.6 million in non-dilutive funding from The Michael J. Fox Foundation for Parkinson's Research across two grant programs to advance its lead program CSM-101. The funding comprises a $2.1 million Targets to Therapies grant for TRPML1 biology validation and biomarker development, and a $5.5 million Therapeutics Pipeline Program grant for IND-enabling studies required to enter first-in-human clinical trials. The company expects these complementary awards to establish the translational foundation for evaluating CSM-101, a TRPML1 agonist targeting lysosomal dysfunction in genetically driven neurodegenerative diseases including Gaucher's disease and Parkinson's disease.PharmiWeb.comCasma Therapeutics Receives MJFF Support to Advance Research on TRPML1 in Parkinson’s DiseaseCasma Therapeutics has been awarded approximately $7.6 million in non-dilutive funding from The Michael J. Fox Foundation for Parkinson's Research across two grant programs to advance its lead program CSM-101, a first-in-class TRPML1 agonist targeting lysosomal dysfunction in Parkinson's disease. The funding comprises a $2.1 million Targets to Therapies grant supporting biomarker development and a $5.5 million Therapeutics Pipeline Program grant supporting IND-enabling studies required to advance into first-in-human clinical trials. The awards reflect external validation of TRPML1 as a therapeutic target and will enable Casma to generate the translational data and regulatory submissions needed to enter clinical evaluation.ParkinsonsnewstodayCasma to develop CSM-101 as treatment for Parkinson’sCasma Therapeutics announced the development of CSM-101, an oral treatment aimed at modifying the progression of Parkinson’s disease and Gaucher disease. The first-in-class small molecule targets the calcium channel TRPML1 to enhance lysosomal function and boost autophagy, with plans to seek FDA approval for clinical testing by 2026. Preclinical studies show that CSM-101 may reduce toxic lipid levels and neuroinflammation in models of both diseases.Endpoints NewsExclusive: After cutting most staff, Casma eyes path to clinic with its first autophagy-boosting drugCasma Therapeutics is unveiling preclinical data for its first autophagy-boosting drug, which aims to enhance brain cells' ability to clear molecular waste. This announcement follows a significant reduction in the company's workforce as it attempts to establish a path toward clinical development.Business Wire BlogCasma Therapeutics Announces CEO TransitionCasma Therapeutics announced that Keith Dionne has stepped down as Chief Executive Officer effective January 13, 2023, with Frank Gentile appointed as the new CEO. Dr. Dionne will remain on the Board of Directors to support the transition, while Dr. Gentile brings over 30 years of pharmaceutical and biotechnology experience to lead the company's autophagy-based drug development platform.